Anti-CD20 antibody plus chemo aids CLL with comorbidityOncology Nurse Advisor(HealthDay News) — For patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting conditions, combining an anti-CD20 antibody (rituximab or obinutuz…
|
Studies Evaluating REVLIMID® (Lenalidomide) in Lymphoma Presented at ASH
Lifescience-online In the first study, Dr. Nishitha M. Reddy evaluated whether maintenance treatment with lenalidomide plus rituximab would result in a clinically significant reduction in relapse rates when compared with lenalidomide alone. DLBCL patients with an … |
|
Ampliação do uso do Rituximab contra linfoma não-Hodgkin folicular no SUS
SRZD Chega em boa hora a liberação do Rituximab no Sistema Único de Saúde (SUS). O remédio mudou a história do linfoma. Inicialmente, para o linfoma agressivo, Linfoma não Hodgkin Difuso de Grandes Células B (LNHDGCB), e posteriormente, para o … |
|
Biologic Makers Thwart Generics: Winning Stocks [Pfizer Inc., Amgen, Inc …
Seeking Alpha Hospira (HSP) and Teva halted late-stage development of follow-on versions of Roche AG’s monoclonal antibody Rituxan (rituximab) — $3.1 billion in domestic sales, trailing 12-months – due to rising R&D costs. Similar to strategies used to delay entry … |
ONO-4059 makes waves in heavily pretreated CLLThe Oncology ReportPatients had already received a median of three prior therapies, including rituximab (84%) and fludarabine (95%), and had no higher priority therapy available to them, said Dr. Gilles Sal…
New Drug Combo Might Help Older, Sicker Patients With LeukemiaPhilly.comThe researchers, whose study was funded by the manufacturer of both obinutuzumab and rituximab, reported that the obinutuzumab-chlorambucil combination improved outcomes for the ol…
Dana-Farber names medical directorHealio… on the evolution of therapy-related acute myeloid leukemia. Head-to-head comparison of obinutuzumab plus chlorambucil vs. rituximab plus chlorambucil in patients with chronic lymphocytic leukemia and co-exist…
Medscape |
CLL Trial Stopped as Ibrutinib Shows Significant Benefits
Medscape The only agent so far to have shown an early definitive overall survival benefit in CLL is rituximab (Rituxan, Genentech/Roche), and hence a combination of ibrutinib with rituximab is very appealing — and trials of this combination are in progress … J&J’s Imbruvica tops Arzerra in phase III trialPMLiVE |
HealthDayNew Drug Combo Might Help Older, Sicker Patients With LeukemiaHealthDayThe researchers, whose study was funded by the manufacturer of both obinutuzumab and rituximab, reported that the obinutuzumab-chlorambucil combination improved outcomes fo…
HealthDay |
Anti-CD20 Antibody + Chemo Benefits CLL With Comorbidity
Monthly Prescribing Reference (HealthDay News) – For patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting conditions, combining an anti-CD20 antibody (rituximab or obinutuzumab) with chemotherapy is associated with improved outcomes, according to … New Drug Combo Might Help Older, Sicker Patients With LeukemiaHealthDay |